Looks promising but
“We plan to create and validate monoclonal antibodies against misfolded TDP43 to select optimal therapeutic candidates for advancement into the clinic."
Do they have any compound identified to target it?
It is clearly gambling stock as any pre-climical work is miles away
“We plan to create and validate monoclonal antibodies against misfolded TDP43 to select optimal therapeutic candidates for advancement into the clinic."
Do they have any compound identified to target it?
It is clearly gambling stock as any pre-climical work is miles away
Recent PMN News
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 05/29/2026 08:15:40 PM
- ProMIS Neurosciences to Participate in Upcoming Conferences in June • GlobeNewswire Inc. • 05/28/2026 02:13:28 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/22/2026 08:34:42 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/22/2026 08:34:08 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/22/2026 08:33:32 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/22/2026 08:31:52 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/22/2026 08:31:04 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/22/2026 08:30:42 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/22/2026 08:30:20 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/12/2026 12:15:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/12/2026 10:45:26 AM
- ProMIS Neurosciences Announces First Quarter 2026 Financial Results and Provides Corporate Highlights • GlobeNewswire Inc. • 05/12/2026 10:30:00 AM
- ProMIS Neurosciences Invited to Participate in the 2026 Bloom Burton & Co. Healthcare Investor Conference • Newsfile • 04/13/2026 11:30:00 AM
- Form ARS - Annual Report to Security Holders • Edgar (US Regulatory) • 04/09/2026 08:03:10 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 04/09/2026 08:02:22 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 04/09/2026 08:01:19 PM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 03/25/2026 09:22:52 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/25/2026 08:34:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/25/2026 12:06:09 PM
- ProMIS Neurosciences Announces Full Year 2025 Financial Results and Provides Corporate Highlights • GlobeNewswire Inc. • 03/25/2026 12:00:00 PM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 03/18/2026 08:16:18 PM
- ProMIS Neurosciences to Present Data on ALS & Parkinsons Disease Programs at Alzheimer’s Disease/Parkinson’s Disease 2026 International Conference (AD/PD™) • GlobeNewswire Inc. • 03/18/2026 12:00:00 PM
